TABLE 4.
Outcome in control and therapy group of sensitized monkeys after kidney transplantation. (Posttransplant histology; comparison treatment group/control group; in order of survival time)
| Animal | Survival (d) | ACR | AMR score (Banff) | Other indications | |||
|---|---|---|---|---|---|---|---|
| Control (n = 6)a | g | ptc | C4d | total | |||
| Monkey 5 | 44 | borderline | 1 | 2 | 3 | 6 | AMR, borderline AR |
| Monkey 6 | 1 | none | 2 | 2 | 2 | 6 | AMR, TMA, hyperacute rejection |
| Monkey 8 | 7 | none | 3 | 0 | 2 | 5 | AMR, TMA |
| Monkey 9 | 27 | borderline | 3 | 1 | 2 | 6 | AMR, borderline AR |
| Monkey 10 | 43 | Banff IIB | 3 | 2 | 2 | 7 | AMR + ACR |
| Monkey 11 | 8 | none | 3 | 1 | 2 | 6 | AMR, TMA |
| AMR score median 6 (IQR 5.75−7) | |||||||
| Therapy (n = 5)b | |||||||
| Monkey 23 | 8 | none | 2 | 1 | 3 | 6 | AMR, TMA |
| Monkey 21 | 16 | none | 0 | 1 | 1 | 2 | CMV + nephritis |
| Monkey 25 | 21 | none | 3 | 1 | 0 | 4 | AMR, CMV + nephritis |
| Monkey 22 | 41 | none | 2 | 0 | 0 | 2 | CMV + nephritis |
| Monkey 24 | >120 | Banff IB | 1 | 0 | 0 | 1 | ACR1B |
| AMR score median 2 (IQR 1−5) | |||||||
AR, acute rejection; AMR, antibody-mediated rejection; g, glomerulitis; ptc, peritubular capillary inflammation; C4d, C4d deposition in walls of peritubular capillaries (immunohistochemistry); TMA, thrombotic microangiopathy; CMV, cytomegalovirus.
a
Monkey 7 (POD3) is excluded from control.
b
Monkey 20 (POD0) is excluded from therapy group for technical complications.